| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $79.2M | +37.9% |
| SG&A Expense | $18.9M | +75.3% |
| Operating Income | -$98.1M | -43.8% |
| Pre-tax Income | -$87.0M | -40.5% |
| Income Tax | $0 | — |
| Net Income | -$87.0M | -40.5% |
| EPS (Basic) | -$2.38 | +59.1% |
| EPS (Diluted) | -$2.38 | +59.1% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $75.3M | +52.6% |
| Short-term Investments | $298.4M | +40.2% |
| Current Assets | $381.5M | +42.7% |
| Total Assets | $385.1M | +43.4% |
| Current Liabilities | $15.5M | +40.2% |
| Total Liabilities | $15.9M | +43.5% |
| Stockholders' Equity | $369.2M | +43.4% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$79.9M | -46.2% |
| Capital Expenditures | $1.9M | +120.7% |
| Investing Cash Flow | -$83.7M | +47.9% |
| Financing Cash Flow | $189.6M | -19.0% |
| Free Cash Flow | -$81.9M | -47.4% |